InsiderTrades.com logo
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing   |   Ad
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Marc D. Kozin net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Marc Kozin Biography and Net Worth

Director of Dicerna Pharmaceuticals

Marc Kozin joined the Dicerna board of directors in 2019. Previously, Mr. Kozin was a Career Strategy Consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012.

Mr. Kozin began his career at L.E.K. in 1987 by helping to establish the firm’s Boston office. He has over 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. He also led the development of L.E.K.’s industry-leading life science strategic planning practice.

Mr. Kozin is Lead Director of UFP Technologies, where he has served as a Director since 2006. In January 2013, he joined the strategy advisory board of HealthCare Royalty Partners, where he is Vice Chairman. He also serves as Chairman of the Board of VBL Therapeutics. On the non-profit side, he serves on the board of The Greenlight Fund.

Since 2012, Mr. Kozin has served on the boards of Endocyte, a small molecule-targeted therapeutic company since sold to Novartis; Dyax, an integrated biotechnology company since sold to Shire; OvaScience, a fertility company since merged with Milendo Therapeutics; and Flex Pharmaceuticals.

What is Marc D. Kozin's net worth?

The estimated net worth of Marc D. Kozin is at least $1.56 million as of March 8th, 2021. Mr. Kozin owns 40,900 shares of Dicerna Pharmaceuticals stock worth more than $1,563,198 as of April 23rd. This net worth estimate does not reflect any other assets that Mr. Kozin may own. Learn More about Marc D. Kozin's net worth.

How do I contact Marc D. Kozin?

The corporate mailing address for Mr. Kozin and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at (617) 621-8097 and via email at [email protected]. Learn More on Marc D. Kozin's contact information.

Has Marc D. Kozin been buying or selling shares of Dicerna Pharmaceuticals?

Marc D. Kozin has not been actively trading shares of Dicerna Pharmaceuticals during the last ninety days. Most recently, on Tuesday, August 10th, Marc D. Kozin bought 3,000 shares of Dicerna Pharmaceuticals stock. The stock was acquired at an average cost of $23.66 per share, with a total value of $70,980.00. Learn More on Marc D. Kozin's trading history.

Who are Dicerna Pharmaceuticals' active insiders?

Dicerna Pharmaceuticals' insider roster includes Shreeram Aradhye (EVP), Bob Brown (EVP), Robert Ciappenelli (Insider), Douglas Fambrough (CEO), Marc Kozin (Director), Regina Paglia (Insider), James Weissman (COO), and Ling Zeng (Insider). Learn More on Dicerna Pharmaceuticals' active insiders.

Marc D. Kozin Insider Trading History at Dicerna Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2021Buy3,000$23.66$70,980.00View SEC Filing Icon  
See Full Table

Marc D. Kozin Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows Marc D Kozin's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $38.22
Low: $38.22
High: $38.22

50 Day Range

MA: $38.12
Low: $37.81
High: $38.25

2 Week Range

Now: $38.22
Low: $19.06
High: $40.14

Volume

N/A

Average Volume

1,344,033 shs

Market Capitalization

$2.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing   |   Ad
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him